Anika Therapeutics (ANIK) Tops Q1 EPS by 45c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.51 +0.34%
Revenue Growth %: +5.9%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.27, $0.45 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $28.11 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $117.2 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
- Teck Receives Highland Valley Copper Operations Strike Notice
- Wabtec (WAB) Tops Q3 EPS by 10c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
